Title: Drug treatment of congenital nephrogenic diabetes insipidus
Abstract: Congenital nephrogenic diabetes insipidus is caused by mutations of Arginine vasopressin receptor 2(AVPR2)/Auqaporin-2(AQP2). The current clinical treatment is aimed at improving symptoms of polydipsia, polyuria. With the deepening research on the pathogenesis, AVPR2 agonists and antagonists, phosphodiesterase antagonists, statins, prostaglandin E receptor agonists can improve mutational AVPR2/AQP2 in synthesis, modification, expression in cells, so achieve the goal of treatment.
Key words:
Congenital nephrogenic diabetes insipidus; Arginine vasopressin receptor 2; Auqaporin-2
Publication Year: 2016
Publication Date: 2016-05-20
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot